Be Biopharma (Be Bio), a specialist in the discovery and development of Engineered B Cell Medicines (BeCM), has closed a $130 million Series B financing round led by Arch Venture Partners.
Bristol Myers Squibb and other new investors also particpated, alongside existing investors including Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and Takeda Ventures.
The round brings the total investment in the Company to date to over $180 million.
The proceeds will advance Be Bio’s proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates toward the clinic.
